Related Experiment Videos
Dexmedetomidine premedication for minor gynecologic surgery
R E Aantaa1, J H Kanto, M Scheinin
1Department of Anesthesiology, Turku University Central Hospital, Finland.
Anesthesia and Analgesia
|April 1, 1990
Summary
Dexmedetomidine, an alpha 2-adrenoceptor agonist, reduced anesthetic needs and lowered blood pressure, heart rate, and norepinephrine levels in women undergoing surgery. The optimal dose for premedication was found to be 0.33-0.67 microgram/kg.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Dexmedetomidine is a novel alpha 2-adrenoceptor agonist.
- Premedication with alpha 2-adrenoceptor agonists can reduce anesthetic requirements.
Purpose of the Study:
- To investigate the effects of different doses of dexmedetomidine on anesthetic requirements, hemodynamics, and plasma catecholamine levels.
- To determine the optimal dose of dexmedetomidine for intravenous premedication in minor surgery.
Main Methods:
- A single-blind study involving 20 healthy women undergoing uterine dilatation and curettage.
- Intravenous administration of four different doses of dexmedetomidine (0.167, 0.33, 0.67, and 1.0 microgram/kg) 15 minutes before anesthesia induction.
- Anesthesia maintained with nitrous oxide/oxygen (70%/30%).
Main Results:
- Dexmedetomidine was well tolerated with mild side effects like tiredness and decreased salivation.
- Thiopental requirements decreased dose-dependently with increasing dexmedetomidine doses (from 400 mg to 180 mg).
- Blood pressure, heart rate, and plasma norepinephrine levels were significantly reduced.
Conclusions:
- Dexmedetomidine effectively reduces anesthetic requirements and improves hemodynamic stability.
- The optimal dose for single-dose intravenous premedication in minor surgery is estimated to be between 0.33-0.67 microgram/kg.
- Dexmedetomidine is a safe and effective agent for premedication in gynecological procedures.